Taken together, our data suggest that upstream SMO inhibitors may not prove efficacious in tumours where a proportion of cells activate GLI via EMT-TFs and instead argue that inhibitors directly targeting GLI may be more effective. The gene discussed is GLI1; the disease is neoplasm.